Last reviewed · How we verify

Intravenous Ketorolac Tromethamine — Competitive Intelligence Brief

Intravenous Ketorolac Tromethamine (Intravenous Ketorolac Tromethamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Pain Management.

phase 2 NSAID COX Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Ketorolac Tromethamine (Intravenous Ketorolac Tromethamine) — Oman Medical Speciality Board. Intravenous Ketorolac Tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Intravenous Ketorolac Tromethamine TARGET Intravenous Ketorolac Tromethamine Oman Medical Speciality Board phase 2 NSAID COX
Celebrex celecoxib Pfizer Inc. (originally Searle/Pharmacia) marketed Nonsteroidal Anti-inflammatory Drug [EPC] COX-2 1998-12-31
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
aspirin and/or clopidogrel aspirin and/or clopidogrel Asan Medical Center marketed Antiplatelet agent COX (aspirin); P2Y12 receptor (clopidogrel)
PCM/Oxy1 PCM/Oxy1 Maastricht University Medical Center marketed Opioid analgesic combination Mu opioid receptor (oxycodone); COX enzymes (paracetamol)
ABS ABS Teva Branded Pharmaceutical Products R&D, Inc. marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2
INF1.0 + IBU INF1.0 + IBU St. Justine's Hospital marketed Interferon alfa + NSAID combination Interferon alfa receptor (IFNAR); COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (NSAID class)

  1. Antibe Therapeutics Inc. · 3 drugs in this class
  2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
  3. Organon and Co · 2 drugs in this class
  4. Apsen Farmaceutica S.A. · 2 drugs in this class
  5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
  6. Behar, Caren, M.D. · 2 drugs in this class
  7. IDEA AG · 2 drugs in this class
  8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
  9. HALEON · 2 drugs in this class
  10. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Ketorolac Tromethamine — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-ketorolac-tromethamine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: